Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations

Cancer Research

Volumn 64, Issue 13, 2004, Pages 4648-4653

  Leuraud, Pascal ^a,d   Taillandier, Luc ^b   Medioni, Jacques ^a,c   Aguirre Cruz, Lucinda ^a,e   Crinière, Emmanuelle ^a   Marie, Yannick ^a   Kujas, Michèle ^a   Golmard, Jean Louis ^a   Duprez, Adrien ^b   Delattre, Jean Yves ^a   Sanson, Marc ^a   Poupon, Marie France ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSTITUT CURIE   (France)

^e NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CARMUSTINE; CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; IFOSFAMIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TELOMERASE; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTOMA; CANCER INHIBITION; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 19P; CHROMOSOME 9P; CHROMOSOME LOSS; CONTROLLED STUDY; ENZYME REACTIVATION; GENE AMPLIFICATION; GENE MUTATION; GLIOMA; HETEROZYGOSITY LOSS; MOUSE; NONHUMAN; NUDE MOUSE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARBOPLATIN; CARMUSTINE; CHROMOSOME ABERRATIONS; DACARBAZINE; GLIOBLASTOMA; HUMANS; IFOSFAMIDE; LOSS OF HETEROZYGOSITY; MICE; MICE, NUDE; MUTATION; OLIGODENDROGLIOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3042738000     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3429     Document Type: Article

References (38)

1. Kleihues P, Cavenee WK, editors. Pathology and genetics of tumours of the central nervous system, 2nd ed. International Agency for Research on Cancer. Lyon, France: IARC Press 2000. pp. 9-69.
2. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer (Phila) 1987;59:1617-25.
3. Salmon I, Dewitte O, Pasteels JL, et al. Prognostic scoring in adult astrocytic tumors using patient age, histopathological grade, and DNA histogram type. J Neurosurg 1994;80:877-83.
4. Sneed PK, Prados MD, McDermott MW, et al. Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery 1995;36:898-903.
5. Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987;21:201-6.
6. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994;74: 1784-91.
7. Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 1990;73:331-44.
8. Leibel SA, Scott CB, Loeffler JS. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol 1994;21:198-219.
9. Lesser GJ, Grossman S. The chemotherapy of high-grade astrocytomas. Semin Oncol 1994;21:220-35.
10. Caimcross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (Bethesda) 1998;90:1473-9.
11. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45.
12. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825-30.
13. Zhu A, Shaeffer J, Leslie S, Kolm P, El-Mahdi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys 1996;34:809-15.
14. Etienne MC, Formento JL, Lebrun-Frenay C, et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin Cancer Res 1998;4:2383-90.
15. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001;61:1122-8.
16. Hoang-Xuan K, He J, Huguet S, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2001;57:1278-81.
17. Sano T, Lin H, Chen X, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 1999;59: 1820-4.
18. Lin H, Bondy ML, Langford LA, et al. Allelic deletion analyses of MMAC/PTEN and DMBTI loci in gliomas: relationship to prognostic significance. Clin Cancer Res 1998;4:2447-54.
19. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Caimcross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001;159:359-67.
20. Miettinen H, Kononen J, Sallinen P, et al. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neurooncol 1999;41:205-11.
21. Bortolotto S, Chiado-Piat L, Cavalla P, et al. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 2000;88:554-7.
22. Nakatani K, Yoshimi N, Mori H, et al. The significant role of telomerase activity in human brain tumors. Cancer 1997;80:471-6.
23. Huang F, Kanno H, Yamamoto I, Lin Y, Kubota Y. Correlation of clinical features and telomerase activity in human gliomas. J Neurooncol 1999;43:137-42.
24. Leuraud P, Taillandier L, Aguirre-Cruz L, et al. Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice. Br J Cancer 2003;89:2327-32.
25. Houghton PJ, Cheshire PJ, Hallman JD 2nd, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
26. He J, Mokhtari K, Sanson M, et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001;60:863-71.
27. Leuraud P, Aguirre-Cruz L, Hoang-Xuan K, et al. Telomerase reactivation in malignant gliomas and loss of heterozygosity on 10p15.1. Neurology 2003;60:1820-2.
28. Zhou XP, Li YJ, Hoang-Xuan K, et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int J Cancer 1999;84:150-4.
29. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
30. Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J Neuropathol Exp Neurol 1995;54:57-64.
31. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 1995;55:20-3.
32. Rainov NG, Dobberstein KU, Bahn H, et al. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol 1997;35:13-28.
33. Newcomb EW, Cohen H, Lee SR, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 1998;8:655-67.
34. lwadate Y, Fujimoto S, Tagawa M, et al. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 1996;69: 236-40.
35. Shiraishi S, Tada K, Nakamura H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer (Phila) 2002;95:249-57.
36. Pollack IF, Finkelstein SD, Woods J, et al. Children's Cancer Group. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002;346: 420-7.
37. Grunnet ML, O'Neill A, Gilbert M, Hellman R. Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy. Clin Neuropathol 2000;19:230-4.
38. Kraus JA, Glesmann N, Beck M, et al. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol 2000;48:89-94.